Vaccine maker Adimmune Corp (國光生技) has gained an approval from Indonesia’s health regulator to conduct phase 1 and 2 clinical trials for its experimental COVID-19 vaccine in the Southeast Asian country, as it aims to tap the Muslim-based market with halal certification, the company said yesterday.
The trials in Indonesia would be Adimmune’s first overseas human tests for its experimental COVID-19 vaccine, after the Ministry of Health and Welfare ordered it to redo its phase 1 trial in Taiwan in December last year to determine the optimal dosage.
Adimmune yesterday said that the Indonesian trials would determine the optimal dosage for its vaccine to generate adequate protection against COVID-19 variants and prove its efficacy.
Photo courtesy of Adimmune Corp
The company plans to recruit 240 healthy adults aged between 18 and 65 to participate in the phase 2 trials, spokesman Pan Fei (潘飛) told the Taipei Times yesterday.
Despite encountering a setback in Taiwan, Adimmune did not modify the formula of its COVID-19 vaccine, dubbed AdimrSC-2f, nor its recombinant protein manufacturing technology, Pan said.
Adimmune’s candidate was developed in spring last year, before the emergence of the SARS-CoV-2 Delta variant. However, the company said it had tested its candidate against the variant in animal tests earlier this year, and that it showed good potential.
Unlike most finished clinical trials, which provide participants with two doses of an experimental vaccine, Adimmune’s clinical trials in Indonesia would give participants three doses, Pan said, adding that the company’s phase 2 trial would require more time and results are expected to be released next year.
The company is to produce the experimental COVID-19 vaccine at its factory in Taiwan and export it to Indonesia for the human trials, in collaboration with the Faculty of Medicine and Health Sciences at Universitas Gadjah Mada, Pan said.
Adimmune said it expects to complete the phase 1 and 2 trials early next year, but it would not seek emergency use authorization (EUA) upon completion, Pan said.
Instead, the company plans to apply to the Indonesian regulator to conduct a phase 3 trial there, he said.
“Timing for applying for an EUA has passed, as there are many available COVID-19 vaccines on the market,” Pan said. “Besides, an EUA is temporary. We aim to conduct the clinical trials without missing any steps and apply for a marketing approval that is valid for a long time.”
If Adimmune gains marketing approval from Indonesia for its COVID-19 vaccines, there is a good chance that the company would be able to provide its vaccine to other Muslim markets, Pan said, adding that the company has obtained a halal certification with its COVID-19 vaccine candidate.
Indonesia has the world’s largest Muslim population, consisting of about 87 percent of its 270.6 million inhabitants.
As with Moderna Inc, Adimmune would consider combining its flu vaccine into COVID-19 vaccine if its candidate is approved, although that mixture would not be a focus for research and development at this time, Pan said.
material SHORTAGE: Even as workers are about to return, Quanta lacks operating supplies, while Pegatron reported its lowest revenues in 11 quarters, the companies said Taiwan’s major Apple Inc supplier cut its outlook for the second quarter, joining a growing list of manufacturers warning about the fallout from lockdowns aimed at containing China’s worst COVID-19 outbreak in two years. Quanta Computer Inc (廣達電腦), which assembles MacBooks, expects a 20 percent quarterly fall in notebook shipments and a squeeze on margins this quarter due to the lockdown, a company representative said on Friday during an earnings call. The impact from supply chain disruptions could last until the end of the year, she said. The company’s Shanghai factory has been operating under tight restrictions since the middle of last month,
The US and the EU were yesterday to announce a joint effort aimed at identifying semiconductor supply disruptions as well as countering Russian disinformation, officials said. Top US officials are visiting the French scientific hub of Saclay for a meetup of the Trade and Technology Council, created last year as China increasingly exerts its technology clout. US officials acknowledged that Russia’s invasion of Ukraine has broadened the council’s scope, but said the Western bloc still has its eye on competition from China. The two sides will announce an “early warning system” for semiconductors supply disruptions, hoping to avoid excessive competition between Western powers
Hon Hai Precision Industry Co (鴻海精密) has made further progress in its expansion into semiconductor manufacturing as its subsidiary teams up with Dagang NeXchange Bhd (DNeX) to build a 12-inch wafer fab in Malaysia. Big Innovation Holdings Ltd (BIH), a wholly owned subsidiary of Hon Hai, has inked a memorandum of understanding (MOU) with DNeX to collaborate on establishing and operating the semiconductor fab in the Southeastern Asian country, it said in a statement released by DNeX on its Web site. The fab is expected to produce 40,000 12-inch wafers per month, deploying 28-nanometer and 40-nanometer process technologies, the statement said. Under
Hotai Motor Co (和泰汽車), which distributes Toyota and Lexus vehicles in Taiwan, yesterday introduced Toyota Motor Corp’s first all-electric sports utility vehicle (SUV), the bZ4X, joining rivals in vying for a share of the nation’s fast-growing electric vehicle market. Starting today, the bZ4X, with a price tag of NT$1.599 million (US$53,780), would be available for online purchase only and customers need to download a special app to place orders, Hotai said. Hotai has received 300 of the electric SUVs, it said, adding that it is not enough to meet robust market demand. A total of 229 electric vehicles were sold in the